Allay Therapeutics Fuels TreeFrog’s Vision: $57.5M Funding Boost to Revolutionize Cell Therapy

TreeFrog Therapeutics, a French-based pioneer in regenerative medicine, is proud to announce the successful closing of a $57.5 million funding round that will accelerate its mission to bring cell therapies to millions of patients globally. Already known for its industry-leading C-Stem technology, TreeFrog is at the forefront of unlocking access to transformative treatments through the mass production of induced pluripotent stem cells and their precise differentiation into ready-to-transplant microtissues. This innovative approach not only ensures unprecedented scalability and cell quality but also promises to bridge a critical gap in current therapeutic pipelines. With a dedicated team of over 150 biophysicists, cell biologists, and bioproduction engineers, TreeFrog’s groundbreaking work has already garnered significant attention. The infusion of $57.5 million will be strategically invested to further accelerate the company’s pipeline of stem cell-based therapies, including advanced research into neurodegenerative disorders such as Parkinson’s Disease. Additionally, the new funds will support expansion initiatives, enhance manufacturing capabilities, and foster new partnerships with leading academic institutions, industry experts, and biotech innovators around the globe. This funding milestone complements the company’s earlier achievements, including the $82 million raised in 2021, highlighting continued investor confidence in TreeFrog Therapeutics' vision and technological prowess. By pushing the boundaries of cell therapy production and co-development, this latest investment is poised to drive the company’s next phase of growth. Ultimately, TreeFrog Therapeutics is reaffirming its commitment to revolutionizing cell-based therapies, ensuring that innovative treatments become an accessible reality for patients worldwide.